P N Tariot

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial
    Pierre N Tariot
    Department of Psychiatry, The Center for Aging and Developmental Biology, Univ of Rochester Medical Center, Rochester, NY, USA
    Am J Geriatr Psychiatry 13:942-9. 2005
  2. ncbi Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib
    Barbara K Martin
    Arch Neurol 65:896-905. 2008
  3. ncbi Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
    P N Tariot
    Department of Psychiatry, University of Rochester Medical Center, New York, USA
    Alzheimer Dis Assoc Disord 15:S26-33. 2001
  4. ncbi Clinical effectiveness of atypical antipsychotics in dementia
    Pierre N Tariot
    University of Rochester Medical Center, Monroe Community Hospital, Psychiatry and Neurobehavioral Therapeutics, Rochester, NY 14620, USA
    J Clin Psychiatry 65:3-4. 2004
  5. ncbi Valproate use in neuropsychiatric disorders in the elderly
    Pierre N Tariot
    University of Rochester Medical Center, Monroe Community Hospital, 435 E Henrietta Road, Rochester, NY 14620, USA
    Psychopharmacol Bull 37:116-28. 2003
  6. ncbi Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    JAMA 291:317-24. 2004
  7. ncbi Current treatment for Alzheimer disease and future prospects
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA
    Alzheimer Dis Assoc Disord 17:S105-13. 2003
  8. ncbi Efficacy of atypical antipsychotics in elderly patients with dementia
    Pierre N Tariot
    Department of Psychiatry and Neurobehavioral Therapeutics, Monroe Community Hospital, University of Rochester Medical Center, Rochester, NY 14620, USA
    J Clin Psychiatry 65:11-5. 2004
  9. ncbi Medical management of advanced dementia
    Pierre N Tariot
    Program in Neurobehavioral Therapeutics, and Department of Psychiatry, Monroe Community Hospital, Rochester, NY, USA
    J Am Geriatr Soc 51:S305-13. 2003
  10. ncbi Use of quetiapine in elderly patients
    Pierre N Tariot
    Department of Psychiatry, University of Rochester School of Medicine, Monroe Community Hospital, Rochester, NY 14620, USA
    J Clin Psychiatry 63:21-6. 2002

Collaborators

Detail Information

Publications45

  1. ncbi Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial
    Pierre N Tariot
    Department of Psychiatry, The Center for Aging and Developmental Biology, Univ of Rochester Medical Center, Rochester, NY, USA
    Am J Geriatr Psychiatry 13:942-9. 2005
    ..It addresses the efficacy, safety, and tolerability of divalproex sodium for the treatment of agitation associated with dementia...
  2. ncbi Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib
    Barbara K Martin
    Arch Neurol 65:896-905. 2008
    ..CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen...
  3. ncbi Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
    P N Tariot
    Department of Psychiatry, University of Rochester Medical Center, New York, USA
    Alzheimer Dis Assoc Disord 15:S26-33. 2001
    ..These results suggest that cholinergic treatments, including galantamine, may stabilize cognitive decline of AD patients. This outcome is likely to make an important difference to patients and caregivers...
  4. ncbi Clinical effectiveness of atypical antipsychotics in dementia
    Pierre N Tariot
    University of Rochester Medical Center, Monroe Community Hospital, Psychiatry and Neurobehavioral Therapeutics, Rochester, NY 14620, USA
    J Clin Psychiatry 65:3-4. 2004
  5. ncbi Valproate use in neuropsychiatric disorders in the elderly
    Pierre N Tariot
    University of Rochester Medical Center, Monroe Community Hospital, 435 E Henrietta Road, Rochester, NY 14620, USA
    Psychopharmacol Bull 37:116-28. 2003
    ..This hypothesis will be addressed in a multicenter trial beginning in 2003...
  6. ncbi Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    JAMA 291:317-24. 2004
    ....
  7. ncbi Current treatment for Alzheimer disease and future prospects
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Rochester, New York, USA
    Alzheimer Dis Assoc Disord 17:S105-13. 2003
    ..Cholinergic and emerging noncholinergic medications will likely prevail as the standards of treatment for years to come...
  8. ncbi Efficacy of atypical antipsychotics in elderly patients with dementia
    Pierre N Tariot
    Department of Psychiatry and Neurobehavioral Therapeutics, Monroe Community Hospital, University of Rochester Medical Center, Rochester, NY 14620, USA
    J Clin Psychiatry 65:11-5. 2004
    ....
  9. ncbi Medical management of advanced dementia
    Pierre N Tariot
    Program in Neurobehavioral Therapeutics, and Department of Psychiatry, Monroe Community Hospital, Rochester, NY, USA
    J Am Geriatr Soc 51:S305-13. 2003
    ..Emerging data have expanded physicians' ability to use pharmacotherapy in patients with advanced dementia. Physicians need to enact the principle that something can be done for our afflicted parents and grandparents...
  10. ncbi Use of quetiapine in elderly patients
    Pierre N Tariot
    Department of Psychiatry, University of Rochester School of Medicine, Monroe Community Hospital, Rochester, NY 14620, USA
    J Clin Psychiatry 63:21-6. 2002
    ....
  11. ncbi Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales
    Pierre N Tariot
    Program in Neurobehavioral Therapeutics, Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA
    Adv Drug Deliv Rev 54:1567-77. 2002
    ..Furthermore, most clinical trials addressing psychopathology have not been mechanism-based and none have attempted an alternative approach, namely, to delay or prevent the emergence of psychopathology...
  12. ncbi A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
    P N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, New York 14620, USA
    J Am Geriatr Soc 49:1590-9. 2001
    ..In summary, effects on cognition, overall dementia severity, and safety and tolerability findings are consistent with previous findings in outpatients and support the use of donepezil in patients with AD who reside in nursing homes...
  13. ncbi A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments
    Y M Greene
    Department of Psychiatry, University of Rochester Medical Center, New York, USA
    J Clin Psychopharmacol 20:350-6. 2000
    ..These data suggest that donepezil HCl merits further study as a potentially viable treatment option for patients with cognitive impairment associated with MS...
  14. ncbi Placebo-controlled study of divalproex sodium for agitation in dementia
    A P Porsteinsson
    Department of Psychiatry and Program in Neurobehavioral Therapeutics, Monroe Community Hospital, Rochester, NY 14620, USA
    Am J Geriatr Psychiatry 9:58-66. 2001
    ..This placebo-controlled study, despite some limitations, suggests possible short-term efficacy, tolerability, and safety of divalproex for agitation in dementia and supports further placebo-controlled studies...
  15. ncbi Pharmacologic therapy for behavioral symptoms of Alzheimer's disease
    P N Tariot
    Department of Psychiatry, University of Rochester Medical Center and Monroe Community Hospital, Rochester, New York, USA
    Clin Geriatr Med 17:359-76. 2001
    ..A rational approach typically hinges on matching the most dominant behavioral target symptoms to the most relevant medication class, the key information of which is summarized...
  16. ncbi Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type
    S Patel
    Department of Psychiatry, Monroe Community Hospital, University of Rochester Medical Center, NY 14620
    J Geriatr Psychiatry Neurol 4:48-51. 1991
    ..He also had some extrapyramidal features and myoclonus. Treatment with amantadine was slightly beneficial. We believe that this report is the first of its kind...
  17. ncbi Impact of molecular medicine on neuropsychiatry: the clinician's perspective
    J M Ryan
    University of Rochester Medical Center, Program in Neurobehavioral Therapeutics, Monroe Community Hospital, 435 E Henrietta Road, Rochester, NY 14620, USA
    Curr Psychiatry Rep 3:355-60. 2001
    ..However, the novel application of new molecular technologies is promising to change the care of neuropsychiatric patients. This review will highlight recent advances in molecular medicine pertaining to neuropsychiatry.Introduction..
  18. ncbi What do people at risk for Alzheimer disease think about surrogate consent for research?
    Scott Y H Kim
    Department of Psychiatry, Center for Behavioral and Decision Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    Neurology 65:1395-401. 2005
    ..Research involving decisionally incapable adults remains an unsettled and controversial policy issue, especially for protocols that involve significant risk to participants. Few data exist to guide policymakers and IRBs..
  19. ncbi A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease
    Louis A Profenno
    Department of Psychiatry, University of Rochester Medical Center, NY 14620, USA
    Curr Alzheimer Res 2:553-8. 2005
    ..Doses of less than 1000 mg/day of divalproex sodium were the maximum tolerated by these outpatients with AD. A larger study of divalproex sodium dose tolerability is needed to define treatment in outpatients with Alzheimer's disease...
  20. ncbi Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies
    Pierre N Tariot
    Memory Disorders Center, Banner Alzheimer s Disease Institute, Phoenix, AZ 85006, USA
    J Clin Psychiatry 67:15-22; quiz 23. 2006
    ..Thus, it is clear that the ChEIs and memantine provide substantial benefits that extend across the spectrum of symptoms of AD, improving outcomes for those who are affected, either directly or indirectly, by this debilitating condition...
  21. ncbi Psychosis and agitation in dementia: should general psychiatrists care?
    Pierre N Tariot
    Memory Disorders Center, Banner Alzheimer s Institute, Phoenix, AZ 85006, USA
    J Clin Psychiatry 69:339-40. 2008
  22. ncbi Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006
    ..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)...
  23. ncbi Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial
    Pierre N Tariot
    Memory Disorders Center, Banner Alzheimer s Disease Institute, Phoenix, Arizona, USA
    Am J Geriatr Psychiatry 14:767-76. 2006
    ....
  24. ncbi Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    N Engl J Med 355:1525-38. 2006
    ..We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease...
  25. ncbi A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease
    Christopher H van Dyck
    Yale University School of Medicine, New Haven, CT 06510, USA
    Alzheimer Dis Assoc Disord 21:136-43. 2007
    ..The type and incidence of adverse events were similar in both groups...
  26. ncbi Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Psychiatry 165:844-54. 2008
    ..The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior...
  27. ncbi National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's Disease (CATIE-AD): baseline characteristics
    M Saleem Ismail
    University of Rochester Medical Center, Program in Neurobehavioral Therapeutics, Monroe Community Hospital, 435 East Henrietta Road, Rochester, NY 14620, USA
    Curr Alzheimer Res 4:325-35. 2007
    ..With the increasing prevalence of AD, clinicians and health care planners should look into future needs of those AD sufferers who are residing in community...
  28. ncbi Managing psychosis in long-term care: treating the whole patient
    Pierre N Tariot
    J Am Med Dir Assoc 4:H2-7. 2003
  29. ncbi Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, NY 14620, USA
    J Am Med Dir Assoc 4:216-9. 2003
    ..This report illustrates that donepezil, and perhaps by analogy other cholinesterase inhibitors as well, can be efficacious in treating the cognitive, functional, and behavioral impairment associated with advanced AD...
  30. ncbi Valproate therapy for agitation in dementia: open-label extension of a double-blind trial
    Anton P Porsteinsson
    Department of Psychiatry, Program in Neurobehavioral Therapeutics, University of Rochester Medical Center and Monroe Community Hospital, Tochester, NY 14620, USA
    Am J Geriatr Psychiatry 11:434-40. 2003
    ..The authors describe an open-label extension of a double-blind, randomized, placebo-controlled study of divalproex sodium in 56 nursing home patients with agitation and dementia...
  31. ncbi Neuroprotective properties of valproate: potential benefit for AD and tauopathies
    Rebekah Loy
    Department of Neurology, Program in Neurobehavioral Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    J Mol Neurosci 19:303-7. 2002
    ..Together, these studies will provide important tests of the hypothesis that valproate, either through inhibition of tau phosphorylation or some other mechanism, is a useful therapeutic agent to modify disease progression in AD...
  32. ncbi Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA
    Schizophr Bull 29:57-72. 2003
    ....
  33. ncbi Academic highlights: emerging therapeutic strategies in Alzheimer's disease
    George T Grossberg
    Departments of Psychiatry and Internal Medicine, St. Louis University Health Center and Wohl Clinic, St. Louis, MO, USA
    J Clin Psychiatry 65:255-66; quiz 283-4. 2004
  34. ncbi Pharmacologic management of agitation in Alzheimer's disease
    Louis A Profenno
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    Dement Geriatr Cogn Disord 17:65-77. 2004
    ..Evidence is reviewed for various medication classes in treating agitation in the patient with Alzheimer's disease, and future treatment strategies may be aimed at delaying or preventing such neuropsychiatric disturbances...
  35. ncbi Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles 90095 1769, USA
    Am J Psychiatry 161:532-8. 2004
    ....
  36. ncbi Psychopharmacologic interventions in nursing homes: what do we know and where should we go?
    J Michael Ryan
    University of Rochester Medical Center, New York 14620, USA
    Psychiatr Serv 53:1407-13. 2002
    ....
  37. ncbi Clinical trials of amyloid-based therapies for Alzheimer's disease
    Pierre N Tariot
    CNS Spectr 12:7-10. 2007
  38. ncbi Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease
    Douglas Galasko
    Department of Neurosciences, University of California at San Diego, San Diego, California, USA
    J Am Geriatr Soc 52:1070-6. 2004
    ..To examine the effect of galantamine on activities of daily living (ADLs) with respect to baseline dementia severity, correlation with cognitive and global function, specific ADLs affected, and maintenance of ADL independence...
  39. ncbi Provisional diagnostic criteria for depression of Alzheimer disease
    Jason T Olin
    Adult and Geriatric Treatment and Preventive Interventions Research Branch, National Institute of Mental Health, Bethesda, MD 20892 9635, USA
    Am J Geriatr Psychiatry 10:125-8. 2002
    ....
  40. ncbi American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition
    Peter V Rabins
    Am J Psychiatry 164:5-56. 2007
  41. ncbi Alzheimer disease: current challenges, emerging treatments
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, New York, USA
    Alzheimer Dis Assoc Disord 17:S98. 2003
  42. ncbi Purchasing or providing nursing home care: can quality of care data provide guidance
    Dan R Berlowitz
    Center for Health Quality, Outcomes, and Economic Research, Bedford Veterans Affairs Hospital, 200 Springs Road, Bedford, MA 01730, USA
    J Am Geriatr Soc 53:603-8. 2005
    ....
  43. ncbi A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type
    Lon S Schneider
    Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    Curr Alzheimer Res 2:541-51. 2005
    ..Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results...
  44. ncbi Pharmacological treatment of neuropsychiatric symptoms of dementia
    Pierre N Tariot
    JAMA 293:2212; author reply 2212. 2005
  45. ncbi Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years
    Gerda G Fillenbaum
    Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA
    Alzheimers Dement 4:96-109. 2008
    ..CERAD materials and data remain available for those wishing to use them...